How Long Has Wegovy Been Around — and What Has Changed Since?

How long has semaglutide itself been around?

Semaglutide's story starts around 2012, when Novo Nordisk began early clinical work on a longer-acting version of the GLP-1 receptor agonist class. The goal at that stage was type 2 diabetes management. Ozempic, the 1 mg weekly injection of semaglutide for diabetes, came first, licensed in Europe in 2018 and reaching the UK shortly after. Rybelsus, a daily oral tablet at 3, 7 and 14 mg strengths, followed as a second diabetes treatment. Neither of those is licensed for weight loss; the distinction matters, and the full history of semaglutide's development covers it in more detail.

The weight-loss formulation arrived through the STEP clinical programme, which ran from around 2018 onwards. STEP 1 (68 weeks, 1,961 adults with obesity or overweight plus a weight-related condition, no diabetes) found an average body-weight reduction of around 15% at 2.4 mg weekly semaglutide compared with placebo. Those results, published in the New England Journal of Medicine, formed the core evidence base for the weight-management licence. So by the time Wegovy reached UK pharmacies, semaglutide itself had roughly a decade of clinical data behind it, a reasonably long track record for a medicine of its class.

When exactly did Wegovy become available in the UK?

The MHRA granted Wegovy its UK marketing authorisation for weight management in 2022. Actual prescribable availability followed in 2023 once supply chains were established, the US launch in mid-2021 had created a global demand spike that complicated the rollout. For patients wanting to understand when Wegovy reached UK pharmacies specifically, the short answer is that 2023 was when most private prescribers could reliably obtain it.

NICE published its recommendation for Wegovy (semaglutide, TA875) in March 2023, which set the terms for NHS use: maximum two years, within a specialist weight-management service, for adults with a BMI of 35 or above and at least one weight-related condition. NHS waiting lists lengthened quickly. Private prescribing through regulated online pharmacies became the practical route for many people who did not qualify for, or could not wait for, NHS treatment. If you want a fuller look at that timeline, this page covers when Wegovy became available in more detail.

What has changed since Wegovy launched?

Quite a lot, and the pace has accelerated. The most significant clinical development was the MHRA's approval of a 7.2 mg semaglutide dose in January 2026, a meaningful step up from the 2.4 mg that had been the maintenance ceiling. The dedicated single-dose 7.2 mg pen was confirmed on 14 April 2026, designed with an auto-dosing mechanism and a covered needle that locks after use. Trial data at 7.2 mg reported average weight loss of around 20.7% over 72 weeks, which narrows the gap with tirzepatide's highest-dose results considerably. The research history behind those higher-dose studies shows how the programme kept expanding after the original licence was granted.

Then, on 11 June 2026, the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer) as the first licensed oral GLP-1 medicine for weight management in the UK. This was a genuinely new category, not an incremental update. The tablet sits in the fridge-free zone: no refrigeration needed, no needles, and you take it first thing in the morning with a small amount of plain water, waiting at least 30 minutes before anything else. For people who found the idea of a weekly injection a barrier, the option hadn't existed before 2026.

Semaglutide also gained a separate MHRA approval on 3 July 2026 for MASH, a form of fatty liver disease, an indication beyond weight management entirely, reflecting how the evidence base for this medicine class continues to grow. As a starting point for understanding the current treatment landscape, the Wegovy treatment overview brings all of this together in one place. Cost context for private treatment is covered on the weight-loss treatments page.

How does the research timeline affect what patients can expect today?

A decade of clinical data means Wegovy enters the consultation room with a well-characterised profile. The common side effects (nausea, diarrhoea, constipation and related GI symptoms) are consistent across the trial programme, tend to be most noticeable when starting or stepping up a dose, and often ease within the first couple of weeks. The NHS medicines page for semaglutide gives a clear patient-level account of what to expect. For a fuller look at what the evidence says about early results specifically, six-week outcomes data from Wegovy trials is covered separately.

The longer the medicine has been studied, the more is known about questions that matter practically: what happens when treatment stops, how to manage side effects during titration, whether the cardiovascular benefits seen in trials translate across populations. None of that replaces a clinical assessment. Our prescribers review every consultation personally, against your full health picture, before any treatment is approved. If you're thinking about whether Wegovy might suit you, checking your eligibility through our free consultation is the right first step.